GlobeNewswire Inc.··NaCuranex Advances Phyto-N Toward Late-Stage Development as Clinical Timeline Solidifies
Curanex advances Phyto-N toward IND submission in Q4 2026, completing manufacturing and toxicology milestones with secured 12-month funding.
CURXclinical trialspharmaceutical development